The fda has granted breakthrough therapy designation to furmonertinib for use as a potential therapeutic option in patients with previously untreated, locally advanced or metastatic nonsquamous. Furmonertinib (ast2818) is an oral, brain penetrant, broadly. A phase 1b study of furmonertinib, an oral, brain penetrant, selective egfr inhibitor, in patients with advanced nsclc with egfr exon 20 insertions International association for the study of lung cancer 2023 world conference on lung cancer
OPEN
